Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Jonas Salk austere", wrote "The New York Times", "Salk the man is a person of great warmth and tremendous enthusiasm. People who meet him generally like him." A Washington newspaper correspondent commented, "He could sell me the Brooklyn Bridge, and I never bought anything before." Award-winning geneticist Walter Nelson-Rees called him "a renaissance scientist: brilliant, sophisticated, driven ... a fantastic creature." He enjoys talking to people he likes, and "he likes a lot of people", wrote the "Times". "He talks quickly, articulately, and often in complete paragraphs." And "He has very little perceptible interest in the things that interest most people—such as